NCT02663128View on ClinicalTrials.gov

A Study of Lanabecestat (LY3314814) in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Healthy
Interventions
DRUG

Lanabecestat

Administered orally

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

AstraZeneca

INDUSTRY